Sulfur 7% Cream Compared With Permethrin 5% Cream for Treating Scabies in Adults
Cure, Sleep and Treatment Satisfaction With Topical Sulfur 7% Versus Permethrin 5% in Scabies: A Randomized Open-Label Trial
1 other identifier
interventional
90
1 country
1
Brief Summary
This study compares two creams used to treat scabies, a common skin condition caused by mites that causes intense itching. Ninety adults with scabies were randomly assigned to receive either sulfur 7% cream or permethrin 5% cream. Sulfur cream was applied once each evening for three nights in a row; permethrin cream was applied once, left on overnight, and repeated after one week. Participants were examined after two weeks and again after four weeks to see whether the scabies had cleared. The study also looked at how quickly itching improved, how much sleep improved, how satisfied participants were with each treatment, how many side effects occurred, and how much each treatment cost. The goal is to help doctors and patients choose between these two widely available, inexpensive treatments based on real-world evidence of how well each one works and how well it is tolerated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Jun 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
CompletedFirst Submitted
Initial submission to the registry
September 6, 2026
CompletedFirst Posted
Study publicly available on registry
September 16, 2026
CompletedSeptember 16, 2026
September 1, 2026
1.9 years
September 6, 2026
September 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Complete cure rate at week 2
Proportion of participants achieving complete cure using the same definition as above, assessed at the earlier time point.
Week 2 after treatment initiation
Complete cure rate at week 4
Proportion of participants achieving complete cure, defined per the 2017 European guideline as resolution of pruritus with no active lesions and no new lesions on clinical examination.
Week 4 after treatment initiation
Secondary Outcomes (7)
Change in pruritus severity
Baseline, week 2, week 4
Change in insomnia symptoms (Athens Insomnia Scale)
Baseline, week 2
Insomnia prevalence
Baseline, week 2
Treatment satisfaction
Week 4
Incidence of treatment-related adverse events
Through week 4
- +2 more secondary outcomes
Study Arms (2)
Arm 1 (Sulfur 7%)
ACTIVE COMPARATORIntervention Type: Drug Intervention Name: Sulfur 7% cream Description: Applied from neck to soles once each evening, left on for 8-14 hours then washed off, for 3 consecutive days. Arm/Group Label: Sulfur 7%
Arm 2 (Permethrin 5%)
ACTIVE COMPARATORIntervention Type: Drug Intervention Name: Permethrin 5% cream Description: Applied from neck to soles as a single overnight application (8-14 hours), repeated once after 7 days. Arm/Group Label: Permethrin 5%
Interventions
Applied from neck to soles once each evening, left on for 8-14 hours then washed off, for 3 consecutive days.
Applied from neck to soles as a single overnight application (8-14 hours), repeated once after 7 days.
Eligibility Criteria
You may qualify if:
- Adults aged 18 years or older
- Clinical diagnosis of ordinary (non-crusted) scabies, established using the 2020 International Alliance for the Control of Scabies (IACS) consensus criteria, category B:
- B1: burrow identified, or
- B2: typical lesions at male genitalia, or
- B3: typical lesions at typical sites plus pruritus and a history of close contact with a person with scabies or itch
You may not qualify if:
- Known allergy or intolerance to sulfur or permethrin
- Pregnant or breastfeeding women
- Hearing, visual, or cognitive impairment preventing reliable self-reporting of symptoms
- Self-discontinuation of study treatment before completion
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Can Tho Dermatology Hospital
Can Tho, Can Tho City, 900000, Vietnam
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tran Gia Hung, PhD
Can Tho University of Medicine and Pharmacy
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer, Department of Dermato-Venereology, Faculty of Medicine
Study Record Dates
First Submitted
September 6, 2026
First Posted
September 16, 2026
Study Start
June 1, 2024
Primary Completion
May 1, 2026
Study Completion
June 1, 2026
Last Updated
September 16, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared. De-identified summary data may be made available from the corresponding author upon reasonable request, subject to institutional approval.